PROK PROKIDNEY CORP

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:

H.C. Wainwright 4th Annual Kidney Virtual Conference

Date:Monday, July 14, 2025
Time:1:30pm ET
Format:Fireside Chat
Webcast:



The live webcast will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at . Investors interested in one-on-one meetings should contact their H.C. Wainwright representative.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .

Investor Contacts:

ProKidney

Ethan Holdaway





LifeSci Advisors, LLC

Daniel Ferry



EN
09/07/2025

Underlying

PROKPROKIDNEY CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Confere...

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 2026Time: 8:15am PSTFo...

January 6, 2026 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Third Quarter 2025 Financial Results and Provides Re...

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have been enrolled; topline results anticipated in Q2 2027Ended the third quarter with $272 million in cash and cash equivalents and marketable securities,...

November 10, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Ri...

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted in a 4.6 mL/min/1.73m2 (78%) improvement in the annual decline of estimated glomerular filtration rate (eGFR) slope in Group 1 (n=24) patientsNo rilparencel-related serious adverse events were observed; the overall study sa...

November 6, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healt...

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in November: Guggenheim Healthcare Innovation Conference (Boston)Date: Wednesday, November 12, 2...

October 29, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Announces Two Abstracts Selected for Presentation at the Ame...

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025 WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX. The tit...

October 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch